Status:
COMPLETED
Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study
Lead Sponsor:
Bursa Yuksek Ihtisas Training and Research Hospital
Conditions:
COVID-19
Methylprednisolone
Eligibility:
All Genders
18+ years
Brief Summary
Aim:There is still not enough data to determine methylprednisolone treatment timing, dosage, duration of use and indication in Covid 19 pneumonia. The aim of this study is to examine the relationship ...
Detailed Description
Covid 19 infection can progress with widespread inflammation and cytokine storm. Induced excessive cytokine release is associated with tissue damage in the lung. Severe inflammatory / oxidative stress...
Eligibility Criteria
Inclusion
- Patients older than 18 years of age who presented to our hospital's emergency clinic
- Patients with pre-diagnosis of severe covid pneumonia
- Patients starting methylprednisolone therapy.
Exclusion
- \<18 years
- Patients with a pre-diagnosis of mild or moderate Covid 19 pneumonia
- Patients not hospitalized in our hospital
- Pregnant patients with Covid 19 pneumonia
- Patients whose 5-methylprednisolone treatment was started in the emergency and discontinued in less than 3 days
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04847687
Start Date
March 1 2021
End Date
April 1 2021
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bursa Yüksek İhtisas EAH
Bursa, Eyalet/Yerleşke, Turkey (Türkiye), 16115